Biosimilar Retacrit<sup>®</sup> (epoetin zeta) in the treatment of chemotherapy-induced symptomatic anemia in hematology and oncology in Germany (ORHEO) - non-interventional study.

Losem, Christoph; Koenigsmann, Michael; Rudolph, Christine

Biosimilar Retacrit^® (epoetin zeta) in the treatment of chemotherapy-induced symptomatic anemia in hematology and oncology in Germany (ORHEO) - non-interventional study.

Losem, Christoph; Koenigsmann, Michael; Rudolph, Christine.

Afiliación

Losem C; Praxis für Hämatologie und Onkologie, Neuss.
Koenigsmann M; Onkologisches Ambulanzzentrum, Marienstr, Hannover.
Rudolph C; Hospira Germany, A Pfizer Company, München, Germany.

Onco Targets Ther ; 10: 1295-1305, 2017.

Article en En | MEDLINE | ID: mdl-28280364

Palabras clave

anemia; biosimilar epoetin zeta; chemotherapy; efficacy; epoetin; erythropoiesis-stimulating agents; real-world; safety

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies Idioma: En Revista: Onco Targets Ther Año: 2017 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google